Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Cell Therapy for Neuroblastoma
NCT02745756Phase 1Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2016
- Primary completion
- Aug 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 1, open-label, single-arm trial of KLH + tumor lysate pulsed dendritic cell vaccine in neuroblastoma, sponsored by Moffitt Cancer Center. Primary endpoint: Occurrence of Sufficient Tumor Cell Lysate and Dendritic Cells at 1 year. Planned start Apr 2016; status: withdrawn.
02
Drugs
KLH + tumor lysate pulsed dendritic cell vaccine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02745756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745756.